Analysts Offer Predictions for Timber Pharmaceuticals, Inc.’s Q1 2024 Earnings (NYSE:TMBR)

Posted by on Apr 12th, 2023

Timber Pharmaceuticals, Inc. (NYSE:TMBR – Get Rating) – Stock analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of Timber Pharmaceuticals in a note issued to investors on Monday, April 10th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.49) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Timber Pharmaceuticals’ current full-year earnings is ($4.50) per share. HC Wainwright also issued estimates for Timber Pharmaceuticals’ Q2 2024 earnings at ($0.42) EPS, Q3 2024 earnings at ($0.37) EPS, Q4 2024 earnings at ($0.35) EPS and FY2024 earnings at ($1.62) EPS.

Timber Pharmaceuticals Trading Down 0.7 %

Shares of TMBR stock opened at $1.49 on Tuesday. The stock has a market capitalization of $4.48 million, a price-to-earnings ratio of -0.11 and a beta of 0.01. Timber Pharmaceuticals has a twelve month low of $1.20 and a twelve month high of $20.50. The stock has a fifty day simple moving average of $2.22 and a two-hundred day simple moving average of $2.98.

Hedge Funds Weigh In On Timber Pharmaceuticals

A number of hedge funds have recently bought and sold shares of TMBR. Bank of New York Mellon Corp purchased a new stake in shares of Timber Pharmaceuticals during the third quarter worth approximately $35,000. Renaissance Technologies LLC grew its holdings in Timber Pharmaceuticals by 37.7% in the 1st quarter. Renaissance Technologies LLC now owns 871,237 shares of the company’s stock valued at $335,000 after buying an additional 238,663 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Timber Pharmaceuticals by 251.7% in the 3rd quarter. Vanguard Group Inc. now owns 4,124,900 shares of the company’s stock valued at $495,000 after buying an additional 2,952,133 shares in the last quarter.

About Timber Pharmaceuticals

(Get Rating)

Timber Pharmaceuticals, Inc operates as a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. Its initial focus is on developing non-systemic treatments for rare dermatologic diseases, including congenital ichthyosis, facial angiofibromas in tuberous sclerosis complex, and other sclerotic skin diseases.

Featured Articles

Earnings History and Estimates for Timber Pharmaceuticals (NYSE:TMBR)

Receive News & Ratings for Timber Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Timber Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.